Table 1.
Technique | Purpose | Target | Technique used on activated cells*? | Relevant studies using CD4+ T cells to establish techniques | Relevant studies using MSCs (Papers discussed in this review) |
---|---|---|---|---|---|
PCR | Presence of viral DNA in cells exposed to HIV-1 | HIV-1 specific DNA such as gag | No |
BM-MSCs: [100] Vessel wall-derived MSCs: [101] Adipose cells/preadipocytes: [32] |
|
qPCR | Genomic integration of HIV-1 into the host genome | Conserved genomic regions of HIV-1 DNA, including pol, gag, tat and/or episomal 2-LTR circles | No | [104–110] | ASCs: [111] |
ddPCR | Conserved genomic regions of HIV-1 DNA, including pol and gag, and/or episomal 2-LTR circles | No | [112–114] | ||
Nested qPCR | Alu elements in the human genome and HIV-1 gag and/or LTR DNA regions | No | [92, 115, 116] |
Vessel wall-derived MSCs: [101] BM-MSCs: [117] |
|
Q4PCR | HIV-1 packaging signal, gag, pol, and env DNA regions | No | [93] | ||
ELISA (conventional and digital) | Productive infection | p24 | No | [118–121] |
Vessel wall-derived MSCs: [101] ASCs: [111] Adipose cells/preadipocytes: [32] |
TILDA | Tat and rev multiply spliced RNA | Yes or no | [96] | ||
Latent infection | |||||
FLIPS | Full-length HIV-1 genomic DNA | No | [124] | ||
qVOA and ELISA | p24 | Yes | [125–128] |
*Activated with latency reversal agents, such as PHA and PMA
Abbreviations: ASCs Adipose-derived mesenchymal stromal/stem cells, (BM)-MSCs (Bone marrow-derived) mesenchymal stromal/stem cells, ddPCR digital droplet polymerase chain reaction, DNA deoxyribonucleic acid, ELISA enzyme-linked immunosorbent assay, env HIV-1 envelope protein, FLIPS full-length individual proviral sequencing, gag HIV-1 group specific antigen, LTR long terminal repeat, MSCs mesenchymal stromal/stem cells, PHA phytohaemagglutinin A, PMA phorbol 12-myristate 13-acetate, pol HIV-1 polymerase, PCR polymerase chain reaction, qPCR quantitative PCR, Q4PCR combined quadruplex qPCR, qVOA quantitative viral outgrowth assay, rev HIV-1 response element protein, RNA ribonucleic acid, tat HIV-1 transactivating protein, TILDA Tat/rev induced limiting dilution assay